Oral Tirzepatide — The Future of Weight Loss Pills - The Molecule That Could Kill the Needle

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Oral Tirzepatide — The Future of Weight Loss Pills - The Molecule That Could Kill the Needle

Listen for free

View show details

About this listen

Ben Synth explores orforglipron, Eli Lilly's experimental oral weight-loss pill showing 27.3 pounds average loss in trials. Unlike injectable tirzepatide, this small-molecule GLP-1 agonist requires no refrigeration or needles, potentially reaching global populations where injectables fail—if FDA approval comes through in 2026.

Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

This content was created in partnership and with the help of Artificial Intelligence AI

No reviews yet